Login to Your Account

Pfizer, Incyte Enter CCR2 Deal Worth Up To $803M

By Randall Osborne

Tuesday, November 22, 2005
Stock-punishing news this fall about a slowdown in development of Incyte Corp''s HIV drug was followed by much happier word Monday, in the form of a potential $803 million research and licensing deal with Pfizer Inc. focused on the Phase II CCR2 antagonist program. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription